Neutralization of MERS coronavirus through a scalable nanoparticle vaccine
| العنوان: | Neutralization of MERS coronavirus through a scalable nanoparticle vaccine |
|---|---|
| المؤلفون: | Ina Balke, Kaspars Tars, Said Dermime, Mona O. Mohsen, Martin F. Bachmann, Zahra Gharailoo, Andris Zeltins, Monique Vogel, Gheyath K. Nasrallah, Byron E. E. Martina, Dominik Rothen, Varghese Inchakalody, Vilija Zeltina |
| المساهمون: | Virology |
| المصدر: | npj Vaccines, 6(1):107. Nature Publishing Group NPJ Vaccines npj Vaccines, Vol 6, Iss 1, Pp 1-9 (2021) Mohsen, Mona O.; Rothen, Dominik; Balke, Ina; Martina, Byron; Zeltina, Vilija; Inchakalody, Varghese; Gharailoo, Zahra; Nasrallah, Gheyath; Dermime, Said; Tars, Kaspars; Vogel, Monique; Zeltins, Andris; Bachmann, Martin F. (2021). Neutralization of MERS coronavirus through a scalable nanoparticle vaccine. NPJ vaccines, 6(1), p. 107. Springer Nature 10.1038/s41541-021-00365-w <http://dx.doi.org/10.1038/s41541-021-00365-wTest> |
| بيانات النشر: | Springer Nature, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Protein vaccines, viruses, Immunology, coronavirus, 610 Medicine & health, Biology, medicine.disease_cause, Neutralization, Epitope, Virus, Article, 03 medical and health sciences, 0302 clinical medicine, Hepatitis E virus, SDG 3 - Good Health and Well-being, MERS, medicine, Pharmacology (medical), Avidity, RC254-282, 030304 developmental biology, Coronavirus, Pharmacology, Hepatitis B virus, 0303 health sciences, nanoparticle, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, virus diseases, RC581-607, Virology, 3. Good health, Genetically modified organism, Infectious Diseases, 030220 oncology & carcinogenesis, Immunologic diseases. Allergy |
| الوصف: | MERS-CoV continues to cause human outbreaks, so far in 27 countries worldwide following the first registered epidemic in Saudi Arabia in 2012. In this study, we produced a nanovaccine based on virus-like particles (VLPs). VLPs are safe vaccine platforms as they lack any replication-competent genetic material, and are used since many years against hepatitis B virus (HBV), hepatitis E virus (HEV) and human papilloma virus (HPV). In order to produce a vaccine that is readily scalable, we genetically fused the receptor-binding motif (RBM) of MERS-CoV spike protein into the surface of cucumber-mosaic virus VLPs. The employed CuMVTT-VLPs represent a new immunologically optimized vaccine platform incorporating a universal T cell epitope derived from tetanus toxin (TT). The resultant vaccine candidate (mCuMVTT-MERS) is a mosaic particle and consists of unmodified wild type monomers and genetically modified monomers displaying RBM, co-assembling within E. coli upon expression. mCuMVTT-MERS vaccine is self-adjuvanted with ssRNA, a TLR7/8 ligand which is spontaneously packaged during the bacterial expression process. The developed vaccine candidate induced high anti-RBD and anti-spike antibodies in a murine model, showing high binding avidity and an ability to completely neutralize MERS-CoV/EMC/2012 isolate, demonstrating the protective potential of the vaccine candidate for dromedaries and humans. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2059-0105 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46a45e168fb3ae3c92c61bc019e7215aTest https://hdl.handle.net/10576/23003Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....46a45e168fb3ae3c92c61bc019e7215a |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20590105 |
|---|